Antagonism between fosfomycin and antipseudomonal penicillins, cefotaxime, and ceftriaxone was observed in Pseudomonas aeruginosa RYC212. Fosfomycin, a non-i-lactam antibiotic that acts on bacterial cell wall synthesis, decreased the expression of penicillin-binding protein 3 and induced j8-lactamase. The antagonistic effect was reduced in the presence of high concentrations of the ,l-lactamase inhibitor tazobactam or in fosfomycin-resistant mutants. We suggest that products resulting from fosfomycin cell wail damage could interact with a system that regulates penicillin-binding protein and I8-lactamase production.
Antibiotic therapy of infections caused by Pseudomonas aeruginosa remains a controversial subject. Combinations of carboxypenicillins, ureidopenicillins, ceftriaxone, or cefotaxime with aminoglycosides are frequently used. New drugs such as ceftazidime, aztreonam, or imipenem have been used as single agents for the treatment of such infections; this avoids the potential toxic effect of aminoglycosides. Nevertheless, bacterial resistance to P-lactam drugs may arise during treatment as a consequence of derepression or activation of chromosomal ,-lactamase (6, 10, 12) , modifications of outer membrane proteins (OMPs) (10, 12) , or altered penicillin-binding proteins (PBPs) (9, 10) . In some cases, combinations of these mechanisms may provoke a synergistic effect, leading to an increased level of resistance (20) .
Fosfomycin, a drug that has remarkable activity against P. aeruginosa, has been suggested as a useful alternative to aminoglycosides when it is used in combination with 1-lactam antibiotics (2) . Fosfomycin inhibits the synthesis of peptidoglycan by blocking the formation of N-acetylmuramic acid (5) , and it is generally believed that this antibiotic acts synergistically with ,B-lactam drugs. In the present report, we describe, for the first time, an important antagonism between fosfomycin and P-lactams in a P. aeruginosa strain. In order to elucidate the molecular basis of this effect, we studied the influence of fosfomycin on ,-lactamase production, OMPs, and PBPs in this P. aeruginosa strain.
( (16) . Sodium dodecyl sulfate-polyacrylamide-urea gel electrophoresis of the OMPs was performed as described previously (8), and proteins were stained with Coomassie brilliant blue.
PBP determinations. Analysis of PBPs was performed on mid-logarithmic-phase cells that were grown at 37°C in LB. Liquid cultures contained antibiotics separately (cefotaxime, 0.5 ,ug/ml; fosfomycin, 4 jig/ml) or in combination (cefotaxime at 4 ,ug/ml plus fosfomycin at 4 jig/ml). PBP analysis of lysed cells was performed by autoradiography after incubation with '25I-labeled ampicillin, as described previously (18, 19) . PBP identification was done as described by Curtis et al. (3, 17) . Each binding essay was performed in the presence or absence of clavulanate (100 ,ug/ml), to reduce the effect of the plasmid or chromosomal 1-lactamases that were presumptively present in the bacterial extracts, on radioactive ampicillin. 
RESULTS
Antibiotic susceptibility and fosfomycin-,-lactam antagonism. P. aeruginosa RYC212 was susceptible to the following P-lactam drugs: ticarcillin (1 ,ug/ml), ticarcillin-clavulanate (<2 and 0.5 ,ug/ml), piperacillin (0.5 ,ug/ml), cefotaxime (2 ,ug/ml), ceftriaxone (2 ,ug/ml), ceftazidime (1 ,ug/ml), aztreonam (0.25 jig/ml), and imipenem (2 ,ug/ml). It was also susceptible to gentamicin and tobramycin (<4 ,ug/ml), amikacin (<16 ,ug/ml), and norfloxacin (<16 ,ug/ml).
The fosfomycin MIC was 32 jig/ml. The MICs for the derivative mutant RYC212F1 were exactly the same as those for the parent strain, except for fosfomycin (MIC, >512 ,ug/ml).
In the double-disk test, fosfomycin produced a distortion of the inhibition zones due to carbenicillin, ticarcillin, piperacillin, mezlocillin, ceftriaxone, or cefotaxime, but had a barely detectable effect (1 to 3 mm of reduction in zone size in proximity to the fosfomycin disk) with ceftazidime or aztreonam. Figure 1 shows a typical image of distortion with cefotaxime. Negative results were obtained for imipenem, aminoglycosides, and norfloxacin. The fosfomycin-resistant mutant RYC212F1 did not show any antagonism between P-lactams and fosfomycin but maintained the classical antagonism between cefoxitin or imipenem and the other P-lactams because of f-lactamase induction (Fig. 1) . When tazobactam, a ,B-lactamase inhibitor, was added to the medium, the distortion of the inhibition zones in proximity to the fosfomycin disk was much less pronounced or was completely abolished. The influence of different concentrations of fosfomycin on the susceptibility of P. aeruginosa RYC212 to cefotaxime, with or without tazobactam, is shown in Fig. 2 growth conditions. When the strain was grown without antibiotics, it produced 4 mU/mg. When the strain was grown in the presence of cefoxitin (4 ,ug/ml), P-lactamase production rose to 50 mU/mg. When it was grown with fosfomycin (4 ,ug/ml) or cefotaxime (0.5 pug/ml), the amounts of P-lactamase were 10 and 8 mU/mg, respectively. In the presence of both fosfomycin and cefotaxime (both at 4 ,ug/ml), the quantity was 16 mU/mg. To ascertain the real value of these differences, the experiments were repeated at least three times in consecutive weeks, and the results were found to be consistent (differences, <3 mU/mg). could be the result of two apparently different mechanisms: (i) ,-lactamase induction mediated by fosfomycin and (ii) a fosfomycin-induced decrease in the expression of PBP 3. The first of these mechanisms was suggested both by the increase in the amount of P-lactamase and because tazobactam inhibited the antagonistic effect. The fosfomycin-resistant mutant did not show fosfomycin-mediated alteration in P-lactam susceptibility or P-lactamase levels, indicating that the activity of fosfomycin against P. aeruginosa RYC212, even at subinhibitory concentrations, was necessary for P-lactamase induction. Since fosfomycin acts on the first step of cell wall biosynthesis (5), it is conceivable that this antibiotic acts as an indirect inducer of ,B-lactamase, perhaps by releasing cell wall fragments with inducer activity. To our knowledge, the only report of a non-,-lactam antibiotic which interacts with PBPs concerns lactivicin. This antibiotic probably acts on a peptidoglycan transpeptidase, because it induces spheroplast formation (13) .
DISCUSSION
As the ,-lactamase inhibitor tazobactam did not completely reverse the antagonistic effects of fosfomycin and 3-lactams, we studied the influence of fosfomycin on the OMP and PBP expression of our P. aeruginosa RYC212 isolate. The OMP pattern was unaffected by the presence of fosfomycin. As expected, the presence of clavulanic acid, which binds to PBP lb, PBP 5, and PBP 6 in P. aeruginosa (18) , decreased the binding of 1251I-labeled ampicillin, but surprisingly, PBP 3 was specifically decreased by fosfomycin. The possibility of an interaction of fosfomycin with
PBPs that would prevent binding with the radioactive P-lactam, was ruled out in complementary control experiments in the presence of 40 ,ug of fosfomycin per ml. It was previously described (21) that fosfomycin decreases the expression of all PBPs except PBP 3 in Staphylococcus aureus. This effect may explain the synergistic effects observed between fosfomycin and some 13-lactam drugs, since PBP 3, the main target of f-lactams in S. aureus, remains unaffected by fosfomycin (21) . Antagonism in our P. aeruginosa strain can be explained by the fact that PBP 3 is a clear target for ,-lactams in this species (4, 9) . We cannot unequivocally eliminate the possibility of a lower affinity to PBP 3 instead of the proposed effect on expression. Nevertheless, our conclusion was supported when identical results were obtained in complementary experiments under saturating conditions with radioactive penicillin. The combination of ,B-lactamase induction and PBP modification by a unique antibiotic is uncommon, and to our knowledge, this is the first time that this phenomenon appears to have been mediated by a non-f-lactam antibiotic. In the search for a single explanation for both of the effects that we observed, it is tempting to suggest that products resulting from cell wall damage caused by fosfomycin could act as recognizable signals for a regulatory gene(s) that affects both P-lactamase and PBP synthesis. Gene fusions with the recently mapped gene of PBP 3 (4) could serve to ascertain this hypothesis.
The observed fosfomycin-ff-lactam antagonism may have clinical relevance. It may contribute to the explanation of why some therapeutic failures occurred when this combination was used in patients with P. aeruginosa infections caused by organisms that were susceptible to both groups of antibiotics (15) . We recently performed a preliminary survey, using the double-disk technique, on the prevalence of this antagonism among clinically relevant P. aeruginosa strains. As expected, none of the seven fosfomycin-resistant (MICs, >64 ,ug/ml) ( 
